.Pharmacolibrary.Drugs.N_NervousSystem.N05B_Anxiolytics.N05BA09_Clobazam.Clobazam .Pharmacolibrary.Drugs.N_NervousSystem.N05B_Anxiolytics.N05BA09_Clobazam.Clobazam| name: | Clobazam | |
| ATC code: | N05BA09 | route: | oral |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 1.3 | L |
| clearance: | 1.7 | L/h |
| other parameters in model implementation | ||
Clobazam is a benzodiazepine derivative used primarily as an adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome and other epileptic disorders. It is also used for short-term relief of severe anxiety. Clobazam is approved and widely used today for epilepsy management.
Pharmacokinetic parameters in healthy adult volunteers following single oral dose administration.
Tolbert, D, & Larsen, F (2019). A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam. Journal of clinical pharmacology 59(1) 7–19. DOI:10.1002/jcph.1313 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30285275
Tolbert, D, et al., & Ette, EI (2016). Drug-metabolism mechanism: Knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions. Journal of clinical pharmacology 56(3) 365–374. DOI:10.1002/jcph.603 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26224203
Yano, I (2019). [Clinical Pharmacometrics for Rational Drug Treatment]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 139(10) 1227–1234. DOI:10.1248/yakushi.19-00124 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31582605